Drug intelligence / Profile preview

TPX-108

Development stage: Preclinical
Lead developer: Tego Science
Modality: Recombinant Proteins and Enzymes
Administration: Topical

Overview

TPX-108 is a chemokine-based biologic being developed by Tego Science for the treatment of cutaneous wounds. As a chemokine, it is designed to facilitate the recruitment and migration of essential cells, such as immune cells and fibroblasts, to the site of injury to promote tissue repair and accelerate the wound healing process. The drug is currently in the preclinical stage of development and is being explored for use in wound healing dressings and topical applications.

Beyond the preview

Go deeper on TPX-108.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TPX-108.

Explore the full profile